Brivanib [cytosol]

Stable Identifier
R-ALL-2023385
Type
ChemicalDrug
Compartment
cytosol
Synonyms
BMS 540215
Locations in the PathwayBrowser
Expand all
General
Brivanib, from Bristol Myers Squibb, is an FGFR and VEGFR inhibitor that has anti-angiogenic effects and that is in clinical trials for endometrial cancer (NCT00888173) (Huynh, 2008). No specific data pertaining to the activity of Brivanib against activated or amplified FGFRs is available, however.
Literature References
PubMed ID Title Journal Year
18829493 Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma

Huynh, H, Ong, HS, Fargnoli, J, Ngo, VC, Tran, E, Thng, CH, Byron, S, Soo, KC, Koong, HN, Chow, P, Chung, A, Pollock, P, Ayers, M

Clin Cancer Res 2008
External Reference Information
External Reference
brivanib [Guide to Pharmacology:5671]
Participates
as a member of
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Cross References
ChEBI
PharmacoDB
PubChem Compound
Cite Us!